Medicare's Bundled Payments for Care Improvement (BPCI) is a voluntary pilot program evaluating bundled payments for several common cardiovascular conditions. Evaluating the external validity of this program is important for understanding the effects of bundled payments on cardiovascular care.
Selective participation represents a potential threat to the external validity of voluntary programs, including BPCI. Prior work suggests that hospitals participating in BPCI may not broadly represent all US acute care hospitals. 4, 5 Investigating participation bias in BPCI Model 2 cardiac bundles is critical for understanding the generalizability of cost and quality outcomes from this pilot and may help policymakers mitigate this bias when designing and implementing future programs, such as BPCI Advanced, a voluntary bundled payment pilot CMS plans to launch in October 2018. 6 Whether participation bias exists in BPCI Model 2 cardiac bundles is unknown. We compared hospitals participating in BPCI Model 2 bundled payments for acute myocardial infarction (AMI), congestive heart failure (CHF), coronary artery bypass graft surgery (CABG), and percutaneous coronary intervention (PCI) with nonparticipants in their health care markets to identify structural and performance characteristics associated with BPCI participation.
Methods
This study was approved by the institutional review board at the Harvard School of Public Health. Medicare claims data had been deidentified prior to use, and informed consent was therefore waived. We used publicly available data from CMS to identify all hospitals that enrolled in BPCI Model 2 bundles for AMI, CHF, CABG, and PCI between October 1, 2013, and January 31, 2017 . Using data from the American Hospital Association's (AHA) Survey of US Hospitals from 2010 to 2013, we identified nonparticipating acute care hospitals in hospital referral regions with at least 1 BPCI participant. Critical access hospitals were excluded. We obtained data on hospital structural characteristics and clinical performance from the AHA survey and CMS' Hospital Compare website including 30-day riskstandardized mortality and readmission rates and clinical volumes for AMI and CHF (list of covariates provided in eAppendix in the Supplement). Data on each hospital's disproportionate share payment were obtained from 2014 Medicare claims. We defined safety net hospitals (SNHs) as having disproportionate sharepayments in the top 10% of hospitals nationally. We compared the structural characteristics and clinical outcomes of BPCI participants and control hospitals using t tests, Wilcoxon tests, and χ 2 tests. We considered a 2-tailed P value less than .05 to be statistically significant. We constructed a multivariable logistic regression model to identify predictors of participation in BPCI Model 2 cardiac bundles. For categorical variables with missing data, we included a missing category alongside other categories in the regression. We excluded patients missing data for one or more continuous variables.
Results
We identified 159 different hospitals participating in BPCI Model 2 cardiac bundles and 1240 control hospitals. Thirty hospitals participated in CABG bundles, 34 in PCI bundles, 52 in AMI bundles, and 114 in CHF bundles; 52 hospitals participated in at least 2 of these bundles. Compared with nonparticipants, BPCI participants were larger and more likely to be privately owned and teaching hospitals. Participants had lower Medicaid bed day proportions (17.0% vs 19.3%; P = .004) and were less likely to be SNHs (n = 4 [2.5%] vs n = 121 [9.8%]; P < .001) ( Table 1) . The BPCI participants had higher mean annual emergency department visits (n = 59 565 vs n = 35 323; P < .001) and higher AMI and CHF discharge volumes and were more likely to have cardiac intensive care units (n = 72 [45.3%] vs n = 315 [25.4%]; P < .001), cardiac catheterization laboratories (n = 140 [88.1%] vs n = 643 [51.9%]; P < .001), and cardiac surgery on site (n = 100 [62.9%] vs n = 371 [29.9%]; P < .001). In addition, BPCI participants had lower risk-standardized 30-day mortality rates for both AMI (13.7% vs 16.6%; P = .001) and CHF (11.3% vs 12.4%; P = .005).
In multivariable analysis, larger hospital size and having a cardiac catheterization laboratory were positively associated with BPCI participation. Being an SNH was strongly and negatively associated with participation (odds ratio, 0.3; 95% CI, 0.1-0.8; P = .01) ( Table 2) .
Discussion
The annual costs of treating cardiovascular disease are projected to quadruple to more than $818 billion by 2030. ensuring the financial sustainability of the US health care system. Bundled payments represent a promising approach for improving quality and reducing unnecessary resource use. 8 The BPCI is the largest study of bundled payments to date. We found significant differences between BPCI model 2 cardiac bundle participants and comparison hospitals with respect to key cardiac capabilities and mortality rates for common cardiovascular conditions. After multivariable adjustment, participating hospitals were significantly more likely to be larger, non-safety net facilities with cardiac catheterization laboratories.
Despite growing interest in using bundled payments to improve care value, little empirical evidence on the merits and risks of bundled payments for cardiovascular disease care or factors associated with success under this new model exists. Our analysis indicates that selection bias could limit the generalizability of cost and quality outcomes data from BPCI model 2 cardiac bundles.
This study has implications for designing and interpreting outcomes from future alternative payment programs, including BPCI Advanced. Specifically, participation bias represents a threat to future voluntary bundled payment pilots, which may struggle to enroll a broadly representative cohort of hospitals, including small hospitals and SNHs. Smaller hospitals may be less likely to participate in voluntary programs because they treat lower volumes of common cardiovascular diseases, lack the capabilities to treat severe and complex cardiovascular disease, and do not possess the administrative and quality improvement infrastructure to track and rapidly improve performance.
9-11 Additionally, SNHs treat outsized proportions of poor and underserved patients, and bundled payment risk adjustment methods do not account for social risk factors. 12,13 Finally, many hospitals contract with private physician groups to staff their facilities rather than directly employing clinicians. This arrangement can complicate efforts to incent high performance within bundles and reduce administrators' enthusiasm to participate in these pilots. These and other barriers must be mitigated to achieve broader participation in future pilots. Policymakers could address these barriers in a few ways. First, they could adjust payments to account for patientlevel social risk factors affecting quality and cost outcomes, which could alleviate concerns managers of SNHs have about participating in pilots.
14 Second, future pilots, including BPCI Advanced, could offer quality improvement assistance or limits to downside risk for underrepresented hospitals to entice them to participate. Third, future pilots could include separate tracks for larger non-SNHs and smaller SNHs; separating these facilities would ensure that hospitals with fundamentally different missions, clinical capabilities, and patient populations are not forced to compete against each other. Fourth, policymakers could reintroduce bundled payment programs with mandatory participation; however, while mandatory participation could solve the generalizability problem, payment adjustments for social determinants of health and quality improvement assistance may still be needed to help some hospitals succeed. b Teaching hospital status was defined using response to the AHA annual survey of US hospitals. Consistent with previous work, major teaching hospitals were defined as being members of the COTH; minor teaching hospitals were defined as non-COTH members, which indicated an affiliation with a medical school on the AHA survey; and all other hospitals were defined as nonteaching hospitals.
c Presence of cardiac surgery capabilities on-site was defined using data from the AHA annual surveys from 2010 to 2013 (preferentially using the most recent available survey data). 7. CDC Foundation. Heart disease and stroke cost america nearly $1 billion a day in medical costs, lost productivity. https://www.cdcfoundation.org/pr /2015/heart-disease-and-stroke-cost-america -nearly-1-billion-day-medical-costs-lost -productivity. Accessed April 30, 2018. , P < .001), and lower mortality rates (AMI, 13.7% vs 16.6%; P = .001; congestive heart failure, 11.3% vs 12.4%; P = .01). Participants were also less likely to be safety-net hospitals (4 [3%] vs 121 [10%]; P < .001).
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These findings have significant implications not only for BPCI, but also for voluntary payment models more broadly. The BPCI program is just one of the payment models that are currently being tested through the Center for Medicare and Medicaid Innovation (CMMI). The CMMI aims to test new approaches to physician and hospital reimbursement much in the same way that a clinical trial is set up to test whether a pharmaceutical or device is associated with better outcomes. Other models that are currently being tested include programs across specialties and care settings, such as the Million Hearts Cardiovascular Disease Risk Reduction Model, Comprehensive Primary Care model, and Accountable Health Communities. Based on the results of CMMI evaluations, such models can be expanded nationwide if they reduce spending without reducing quality or improve quality without increasing spending.
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Of course, to determine whether nationwide expansion could be reasonably expected to follow similar patterns and achieve similar cost and quality outcomes as the test case, one would want to know if the test participants are similar to the broader population to whom the program would ultimately be 
